| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
2,506,667 |
$27,523,203 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
2,094,650 |
$22,999,257 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Actuate Co-Invest II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
1,259,427 |
$13,828,508 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Clinical Opportunity Fund, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
2,643,705 |
$13,218,525 |
$5.00 |
21 Jun 2023 |
Directly held by Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
980,433 |
$10,765,154 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
573,394 |
$6,295,866 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Actuate Co-Invest III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
525,797 |
$5,773,251 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund I, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
1,023,442 |
$5,117,210 |
$5.00 |
21 Jun 2023 |
Directly held by Bios Fund II QP, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
2,021,906 |
$5,014,326 |
$2.48 |
19 Sep 2025 |
By Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
404,814 |
$4,444,857 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund III NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
383,791 |
$4,214,025 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund III, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
799,467 |
$3,997,335 |
$5.00 |
21 Jun 2023 |
Directly held by Bios Fund I, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
1,424,014 |
$3,531,554 |
$2.48 |
19 Sep 2025 |
By Bios Memory SPV I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
307,538 |
$3,376,767 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund I QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
300,749 |
$3,302,224 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Actuate Co-Invest I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
300,143 |
$3,295,570 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund II, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
467,613 |
$2,338,065 |
$5.00 |
21 Jun 2023 |
Directly held by Bios Fund I QP, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
436,173 |
$2,180,865 |
$5.00 |
21 Jun 2023 |
Directly held by Bios Azitra Co-Invest I, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
426,944 |
$2,134,720 |
$5.00 |
21 Jun 2023 |
Directly held by Bios Fund III NT, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
404,767 |
$2,023,835 |
$5.00 |
21 Jun 2023 |
Directly held by Bios Fund III, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
313,250 |
$1,566,250 |
$5.00 |
21 Jun 2023 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
131,248 |
$1,441,103 |
$10.98 |
27 Jun 2025 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
196,428 |
$1,374,996 |
$7.00 |
27 Jun 2025 |
Directly held by Bios 2024 Co-Invest, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
500,095 |
$1,240,235 |
$2.48 |
19 Sep 2025 |
By Bios Clinical Opportunity Fund, LP |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
373,178 |
$1,153,120 |
$3.09 |
13 Jun 2025 |
By Bios Fund II QP, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
418,926 |
$1,038,936 |
$2.48 |
19 Sep 2025 |
By Bios Fund I, LP |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
323,335 |
$999,105 |
$3.09 |
13 Jun 2025 |
By Bios Fund I, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
385,248 |
$955,415 |
$2.48 |
19 Sep 2025 |
By Bios Memory SPV II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
84,917 |
$932,388 |
$10.98 |
27 Jun 2025 |
Directly held by BP Directors, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
326,733 |
$810,297 |
$2.48 |
19 Sep 2025 |
By Bios Fund III NT, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
309,748 |
$768,175 |
$2.48 |
19 Sep 2025 |
By Bios Fund III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
69,375 |
$761,737 |
$10.98 |
27 Jun 2025 |
Directly held by Circle K Invesco, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
137,000 |
$685,000 |
$5.00 |
21 Jun 2023 |
Directly held by Bios Fund II NT, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
135,808 |
$679,040 |
$5.00 |
21 Jun 2023 |
Direct |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
60,973 |
$669,483 |
$10.98 |
27 Jun 2025 |
Directly held by Aaron G.L. Fletcher |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
255,765 |
$634,297 |
$2.48 |
19 Sep 2025 |
By Bios Fund II QP, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
245,029 |
$607,671 |
$2.48 |
19 Sep 2025 |
By Bios Fund I QP, LP |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
189,117 |
$584,371 |
$3.09 |
13 Jun 2025 |
By Bios Fund I QP, LP |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
3,727,597 |
$559,139 |
$0.1500 |
02 May 2025 |
By Bios Fund III QP, LP |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
114,272 |
$353,100 |
$3.09 |
13 Jun 2025 |
by Bios Fund II, LP |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
1,876,624 |
$281,493 |
$0.1500 |
02 May 2025 |
By Bios Fund II QP, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
78,298 |
$194,179 |
$2.48 |
19 Sep 2025 |
By Bios Fund II, LP |
| SWK Holdings Corp |
Director |
Common Stock |
9,873 |
$177,220 |
$17.95 |
31 Dec 2021 |
Direct |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
49,957 |
$154,367 |
$3.09 |
13 Jun 2025 |
By Bios Fund II NT, LP |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
997,433 |
$149,614 |
$0.1500 |
02 May 2025 |
By BIOS Incysus Co-Invest I, LP |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
26,093 |
$100,718 |
$3.86 |
13 Jun 2025 |
By BP Directors, LP |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
601,980 |
$90,297 |
$0.1500 |
02 May 2025 |
By Bios Fund III, NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
8,056 |
$88,454 |
$10.98 |
27 Jun 2025 |
Directly held by KF Legacy Trust U/A/D December 7, 2016 |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
8,056 |
$88,454 |
$10.98 |
27 Jun 2025 |
Directly held by MF Legacy Trust U/A/D December 7, 2016 |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
574,432 |
$86,164 |
$0.1500 |
02 May 2025 |
By Bios Fund II, LP |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
570,724 |
$85,608 |
$0.1500 |
02 May 2025 |
By Bios Fund III, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
34,238 |
$84,910 |
$2.48 |
19 Sep 2025 |
By Bios Fund II NT, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
13,106 |
$65,530 |
$5.00 |
21 Jun 2023 |
Directly held by KF Legacy Trust |
| Azitra Inc |
10%+ Owner |
Common Stock |
13,106 |
$65,530 |
$5.00 |
21 Jun 2023 |
Directly held by MF Legacy Trust |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
56,229 |
$47,232 |
$0.8400 |
19 Sep 2025 |
Direct |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
251,211 |
$37,681 |
$0.1500 |
02 May 2025 |
By Bios Fund II NT, LP |
| IN8BIO, INC. |
10%+ Owner |
Pre-Funded Warrants |
2,431,763 |
|
|
02 May 2025 |
By Bios Clinical Opportunity Fund, LP |
| IN8BIO, INC. |
10%+ Owner |
Series C Warrant |
709,040 |
|
|
02 May 2025 |
By Bios Clinical Opportunity Fund, LP |
| IN8BIO, INC. |
10%+ Owner |
Stock Option |
85,000 |
|
|
02 May 2025 |
Indirect |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
71,428 |
|
|
27 Jun 2025 |
Directly held by Bios 2024 Co-Invest, LP |
| TFF Pharmaceuticals, Inc. |
Director |
Stock Options (Right to Buy) |
33,475 |
|
|
29 Dec 2022 |
To BP Directors for the benefit of Reporting Person |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Stock Options |
31,884 |
|
|
12 Aug 2024 |
Directly held by BP Directors, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Stock Options |
15,000 |
|
|
22 May 2025 |
Direct |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Stock Options |
15,000 |
|
|
12 Aug 2024 |
Directly held by Aaron G.L. Fletcher |
| Cue Biopharma, Inc. |
Director |
Stock Option (right to buy) |
10,000 |
|
|
03 Jan 2023 |
Direct |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Convertible Note |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Clinical Opportunity Fund, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series A Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series A Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund I QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Actuate Co-Invest I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Actuate Co-Invest I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Actuate Co-Invest II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Actuate Co-Invest III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
14 Aug 2024 |
Directly held by Bios Fund II QP, LP |
| Azitra Inc |
10%+ Owner |
Convertible Notes |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund III, LP |
| Azitra Inc |
10%+ Owner |
Convertible Notes |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund III NT, LP |
| Azitra Inc |
10%+ Owner |
Convertible Notes |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund III QP, LP |
| Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Azitra Co-Invest I, LP |
| Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund II, LP |
| Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund II NT, LP |
| Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund II QP, LP |
| Azitra Inc |
10%+ Owner |
Series A Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund I, LP |
| Azitra Inc |
10%+ Owner |
Series A Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund I QP, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund III, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund III NT, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund III QP, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund II, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund II NT, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
21 Jun 2023 |
Directly held by Bios Fund II QP, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Stock Option (right to buy) |
0 |
|
|
19 Sep 2025 |
Direct |
| IN8BIO, INC. |
10%+ Owner |
Series A Warrant |
0 |
|
|
02 May 2025 |
By Bios Clinical Opportunity Fund, LP |
| IN8BIO, INC. |
10%+ Owner |
Series B Warrant |
0 |
|
|
02 May 2025 |
By Bios Clinical Opportunity Fund, LP |